Bayer is seeking people living with liver cancer to provide feedback on an upcoming Phase 1, first-in-human HCC study. Participants will have the opportunity to review the study protocol and advise the Bayer team on ways to optimize the study's conduct to improve the patient experience. You will also have an opportunity to review study materials (e.g., informed consent, patient brochures, etc.) to confirm their relevance and comprehension.
Since this is a global study, Bayer is seeking US and those outside of the US to provide input.
They will compensate you for your time and effort. The first meeting is anticipated to take place in early August 2024.
Please contact Dr. Pooja Merchant (pooja.merchant@bayer.com) if you are interested in exploring this opportunity.
Bayer remains committed to incorporating the patient perspective as early as possible in our study design to ensure they are developing meaningful and relevant therapies.
